90,135 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 90,135 shares of the company’s stock, valued at approximately $3,359,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its position in shares of IDEAYA Biosciences by 171.1% in the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock worth $32,000 after buying an additional 580 shares during the period. ANTIPODES PARTNERS Ltd lifted its position in IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares during the period. Quantbot Technologies LP bought a new stake in IDEAYA Biosciences during the second quarter worth about $43,000. Global Retirement Partners LLC purchased a new stake in IDEAYA Biosciences in the fourth quarter worth about $61,000. Finally, Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on IDYA. Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Royal Bank Of Canada reduced their price objective on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a research report on Tuesday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Friday, July 17th. Wedbush boosted their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Truist Financial cut their target price on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.12.

Insider Transactions at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares in the company, valued at approximately $1,058,904.66. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.70% of the stock is currently owned by insiders.

IDEAYA Biosciences Stock Down 4.0%

Shares of NASDAQ:IDYA opened at $40.11 on Friday. The firm’s 50 day moving average price is $37.17 and its 200-day moving average price is $33.17. The stock has a market capitalization of $3.52 billion, a PE ratio of -20.68 and a beta of -0.10. IDEAYA Biosciences, Inc. has a twelve month low of $23.23 and a twelve month high of $42.68.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The company had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. During the same quarter last year, the firm posted ($0.88) earnings per share. The company’s revenue was up 8800.0% compared to the same quarter last year. Analysts expect that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.